Firivumab
Modify Date: 2024-04-12 16:15:22
Firivumab structure
|
Common Name | Firivumab | ||
|---|---|---|---|---|
| CAS Number | 1443004-15-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of FirivumabFirivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice[1][2][3]. |
| Name | Firivumab |
|---|
| Description | Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.1-1.3 μg/mL (H1N1), 0.78 μg/mL (H2N2), 0.48-0.65 μg/mL (H5N1), 4.69 μg/mL (H6N1), 4.69 μg/mL (H6N2), 2.34 μg/mL (H8N4), 1.3 μg/mL (H8N8), 2.08 μg/mL (H9N2) and 20.83 μg/mL (H12N7)[1] |
| In Vivo | Firivumab (CT-P22; CT120; 7.5-30 mg/kg; 腹腔给药; 感染后 24 小时) 在 >15 mg/kg 治疗组中对 H1N1 病毒显示 100% 的保护，在 7.5 mg/kg 治疗组中显示 70% 的保护[1]。 Firivumab (添加 7.5 mg/kg CT120 和 7.5 mg/kg CT149) 在 A/California/04/09 (H1N1) 处理的小鼠中表现出全面保护[1]。 Animal Model: Six- to nine-week-old female BALB/c mice with A/California/04/09 (H1N1) and A/Philippines/2/1982 (H3N2)[1] Dosage: 7.5, 15, 30 mg/kg Administration: IP; Twenty-four hours post-infection Result: Showed 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group. Could not protect mice from H3N2 infection. |
| References |
| No Any Chemical & Physical Properties |